Meeting of the Working Group on Health Policy in Munich
In the middle of February, BIO Deutschland’s Working Group on Health Policy met at MediGene AG in Munich. Topics on the agenda included the latest revision to the Medication Law and the measures to be undertaken by the association in the light of the cabinet resolution.
In addition, BIO Deutschland’s stance on subjects including cost-benefit evaluation, second opinion procedures, therapy indications, off-label use of medication in clinical trials, and medication for rare diseases (orphan drugs) was discussed at the meeting.
The next meeting is scheduled to take place at Frenesius Biotech in Munich.